Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 24;67(1):e0148322.
doi: 10.1128/aac.01483-22. Epub 2023 Jan 9.

Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency

Affiliations

Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency

Matthew J Reichlen et al. Antimicrob Agents Chemother. .

Abstract

The sigmoid Emax model was used to describe the rRNA synthesis ratio (RS ratio) response of Mycobacterium tuberculosis to antimicrobial concentration. RS-Emax measures the maximal ability of a drug to inhibit the RS ratio and can be used to rank-order drugs based on their RS ratio effect. RS-EC90 is the concentration needed to achieve 90% of the RS-Emax, which may guide dose selection to achieve a maximal RS ratio effect in vivo.

Keywords: Mycobacterium tuberculosis; RS ratio; antibiotic; antimicrobial; drug effects; drug therapy; precursor rRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. M.I.V., G.T.R., N.D.W. are listed as inventors on patent #U.S. Patent No. 16/632,310 for “Methods Of Evaluating Treatment Efficacy and/or Treatment Duration In Mycobacterial Diseases.”

Figures

FIG 1
FIG 1
RS ratio concentration response sigmoid Emax models and correlations with conventional metrics. (A) The percent effect on the RS ratio was defined as the percent decrease in the RS ratio after 48 h of drug exposure, compared to the pre-drug exposure value. The percent effect was plotted as a function of the log-transformed concentrations of the drug, as described by the equation: Y = Emin + (Emax − Emin) / (1 + 10log[EC50]−X· Hill slope), with Y indicating the percent effect and X indicating the log-transformed concentration. All of the dose response curves were generated, and all of the data were analyzed, using GraphPad Prism 9. Curves were fit to the observed data using least-squares regression and medium convergence criteria (maximum iterations = 1,000). No y axis weighting or outlier exclusion filters were applied. The best-fit and range values (defined as 95% confidence intervals) for the RS-Emax, RS-Emin, RS-EC50, and Hill slopes are listed in Table 1 for each drug. Unstable parameters for which a 95% confidence interval could not be determined are indicated. The best-fit curves are depicted with a solid black line. Additional dashed lines depict the RS-Emax (green horizontal), mean control RS ratio response at 48 h (gray horizontal), and RS-EC90 (yellow vertical). (B) The correlations between the standard MIC (circles) or MICextr (triangles) with RS-EC90. (C) The correlation between the ΔCFU-Emax and RS-Emax. Linezolid was not included in the correlations due to its inverse effect on the RS ratio.

References

    1. Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. 2018. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuber Lung Dis 22:239–245. doi:10.5588/ijtld.17.0660. - DOI - PubMed
    1. Davies GR. 2010. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb) 90:171–176. doi:10.1016/j.tube.2010.03.007. - DOI - PubMed
    1. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PPJ, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W, Centers for Disease Control and Prevention . 2011. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 184:972–979. doi:10.1164/rccm.201105-0827WS. - DOI - PMC - PubMed
    1. Dooley KE, Phillips PPJ, Nahid P, Hoelscher M. 2016. Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev 102:116–122. doi:10.1016/j.addr.2016.01.014. - DOI - PMC - PubMed
    1. J Libardo MD, Boshoff HI, Barry CE, 3rd. 2018. The present state of the tuberculosis drug development pipeline. Curr Opin Pharmacol 42:81–94. doi:10.1016/j.coph.2018.08.001. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances